Anyhow, these data strength the interest for potential clinical applications of Nutlin-3 also in light of previous reports suggesting that small-molecule p53 activators could have clinical benefits as chemoprotectants for cancer patients bearing p53-mutant tumors, by protecting normal cells from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics [41,42]. The gene discussed is TP53; the disease is cancer.